MOREPENLAB
NSE · EQ
₹23.57
-0.13 (-0.55%)
Market Stats
Open
--
Prev. Close
--
Low
₹113.00
High
₹123.55
Circuit (Lower–Upper)
52-Week (Low–High)
Market Depth
Morepen Laboratories Limited develops, manufactures, markets, and sells active pharmaceutical ingredients (APIs), branded and generic formulations, and home health products in India, the United States, and internationally. The company offers APIs for anti-histaminic, anti-asthmatic, anti-lipemic, anti-hypertensive, anti-diabetic, anti-coagulant, anti-ulcerative, and anti-depressant drugs; and home diagnostic products, such as air purifiers, sphygmomanometers, blood glucose test strips, blood pressure monitors, breathe free vaporizers, stethoscopes, digital thermometers, blood glucose monitors, nebulizers, heat belts, and pulse oximeters. It also provides OTC and healthcare products, including fever X for fever; Pain X for pain; Fiber-X for constipation; sat isabgol; Acidity X for acidity; Burnol, a first degree/minor burns cream; and formulations for nutrition and probiotics, gastroenterology, antibiotics, gynecology, anti-allergic, and central nervous system, as well as cardiology, diabetology, and nutraceuticals. The company offers over the counter products under the Dr. Morepen brand name. Morepen Laboratories Limited was incorporated in 1984 and is based in Gurugram, India.
Market Cap
₹ 6,769.42 Cr
Current Price
₹ 23.57
High / Low
--
Stock P/E
45.88
Book Value
₹ 22.75
Dividend Yield
0.16 %
ROCE
10.19 %
ROE
9.75 %
Face Value
₹ 2
Showing: Net Sales
| Metric | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
Net Sales | 1,188.06 Cr | 1,546.83 Cr | 1,417.53 Cr | 1,690.43 Cr | 1,811.58 Cr |
Total Expenditure | 1,069.54 Cr | 1,410.15 Cr | 1,338 Cr | 1,531.81 Cr | 1,637.51 Cr |
Operating Profit | 118.51 Cr | 136.67 Cr | 79.53 Cr | 158.62 Cr | 174.07 Cr |
Other Income | 12.07 Cr | 20.1 Cr | 6.13 Cr | 13.97 Cr | 18.36 Cr |
Interest | 1.79 Cr | 2.43 Cr | 1.98 Cr | 3.71 Cr | 8.34 Cr |
Depreciation | 30.28 Cr | 27.64 Cr | 27.93 Cr | 33.47 Cr | 28.98 Cr |
Exceptional Items | 0 Cr | 0 Cr | 0 Cr | 0 Cr | 0 Cr |
Profit Before Tax | 98.51 Cr | 126.7 Cr | 55.76 Cr | 135.42 Cr | 155.11 Cr |
Tax | 1.42 Cr | 25.02 Cr | 17.08 Cr | 38.8 Cr | 37.09 Cr |
Profit After Tax | 97.09 Cr | 101.68 Cr | 38.68 Cr | 96.62 Cr | 118.02 Cr |
Adjustments | 0 Cr | 0 Cr | 0 Cr | -0.46 Cr | 0.01 Cr |
Consolidated Net Profit | 97.09 Cr | 101.68 Cr | 38.68 Cr | 96.16 Cr | 118.02 Cr |
Adjusted EPS (Rs.) | 2.16 Cr | 2.13 Cr | 0.76 Cr | 1.88 Cr | 2.15 Cr |
Showing: Debtor Days
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 25 Cr | 40 Cr | 31 Cr | 31 Cr | 30 Cr | 42 Cr | 23 Cr | 22 Cr | 30 Cr | 27 Cr | 49 Cr | 34 Cr |
Inventory Days | 70 Cr | 82 Cr | 63 Cr | 60 Cr | 62 Cr | 100 Cr | 84 Cr | 107 Cr | 119 Cr | 192 Cr | 221 Cr | 220 Cr |
Days Payable | 25 Cr | 15 Cr | 24 Cr | 37 Cr | 34 Cr | 29 Cr | 12 Cr | 4 Cr | 6 Cr | 9 Cr | 9 Cr | 35 Cr |
Cash Conversion Cycle | 69 Cr | 107 Cr | 70 Cr | 54 Cr | 59 Cr | 112 Cr | 95 Cr | 125 Cr | 142 Cr | 210 Cr | 261 Cr | 220 Cr |
Working Capital Days | -9 Cr | -3 Cr | -5 Cr | 1 Cr | 5 Cr | 17 Cr | 16 Cr | 23 Cr | 12 Cr | 11 Cr | 19 Cr | -16 Cr |
ROCE % | - | 27.00% | 17.00% | 24.00% | 32.00% | 35.00% | 21.00% | 11.00% | 7.00% | 5.00% | 5.00% | 5.00% |
No peer comparison data available.
No bulk deals found for this stock.
Morepen Laboratories Limited develops, manufactures, markets, and sells active pharmaceutical ingredients (APIs), branded and generic formulations, and home health products in India, the United States, and internationally. The company offers APIs for anti-histaminic, anti-asthmatic, anti-lipemic, anti-hypertensive, anti-diabetic, anti-coagulant, anti-ulcerative, and anti-depressant drugs; and home diagnostic products, such as air purifiers, sphygmomanometers, blood glucose test strips, blood pressure monitors, breathe free vaporizers, stethoscopes, digital thermometers, blood glucose monitors, nebulizers, heat belts, and pulse oximeters. It also provides OTC and healthcare products, including fever X for fever; Pain X for pain; Fiber-X for constipation; sat isabgol; Acidity X for acidity; Burnol, a first degree/minor burns cream; and formulations for nutrition and probiotics, gastroenterology, antibiotics, gynecology, anti-allergic, and central nervous system, as well as cardiology, diabetology, and nutraceuticals. The company offers over the counter products under the Dr. Morepen brand name. Morepen Laboratories Limited was incorporated in 1984 and is based in Gurugram, India.
Sector
Healthcare
Industry
Pharmaceuticals & Biotechnology
Basic Industry
Pharmaceuticals
MOREPENLAB
NSE · EQ
₹23.57
-0.13 (-0.55%)
Market Stats
Open
--
Prev. Close
--
Low
₹113.00
High
₹123.55
Circuit (Lower–Upper)
52-Week (Low–High)
Market Depth